The trial will offer participants a new, twice-yearly injectable PrEP (pre-exposure prophylaxis) medicine called Lenacapivir.

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Lenacapavir works by stopping HIV from making more copies of itself and so getting into someone's immune cells. What made ...

Despite being effective, PrEP uptake in Europe remains low due to issues like cost, access, and stigma, hindering its ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.